Navigation Links
Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better
Date:5/28/2009

People with diabetes can improve their general health and self-care management by using simple tools to uncover links between lifestyle and blood glucose levels.

INDIANAPOLIS, May 28 /PRNewswire/ -- Roche, the maker of ACCU-CHEK(R) blood glucose monitoring systems and insulin pumps, announced today the availability of two new tools that can help patients pinpoint food and lifestyle choices that have the biggest impact on their blood glucose levels, giving them greater control in their everyday battles against diabetes.

As the world leader in diabetes diagnostics, Roche is rolling out the ACCU-CHEK Testing in Pairs and ACCU-CHEK 360-degree View tools as a way to help adults, children and teens manage their diabetes more easily and more effectively. The initiative is part of Roche's Behavior Change through Patient Engagement (sm) program.

"Diabetes is a 24/7 disease that doesn't give patients a day off," said Dan Kane, vice president of marketing for Roche Diabetes Care North America. "It's relentless, and we understand how difficult it can be to stay motivated, especially when it's not clear what affects blood sugar levels or why the numbers on a patient's meter rise and fall like they do. These simple tools bring clarity to the meaning of those numbers and, more importantly, help patients better understand what influences their results -- and what they can do to improve them."

The ACCU-CHEK Testing in Pairs tool is a simple paper-based way to track blood sugar responses to everyday situations like stress, exercise and eating out. By comparing before-and-after readings around single events for seven days, patients can zero in on one thing that makes a difference for them, instead of trying to change everything at once.

The ACCU-CHEK 360-degree View tool is a paper chart that offers a seven-point profile of blood glucose control. In just three days, it gives a more complete picture of the effectiveness of prescriptions, as well as how food portions affect blood glucose and energy levels. Discovering these patterns may help patients and their healthcare providers quickly see if adjustments are needed.

"By tracking results over time, patients see how balanced meals and medication--even changes brought about by these simple tools--alter blood sugar levels," Kane said. "The initiative not only helps people understand their numbers better, it allows them to take a greater role in developing effective plans with their healthcare providers for more successful outcomes."

For a free download and more information, please visit accu-chek.com/testinginpairs and accu-chek.com/success.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management--from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.

For more information, please visit accu-chek.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss francs. Genentech (United States) is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical (Japan). For more information, visit www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

    For further information, please contact:
    Julie Vincent
    Public Relations Manager
    ACCU-CHEK Brand
    julie.vincent@roche.com
    317-521-1910


'/>"/>
SOURCE Roche Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Fluxion Biosciences announced today that Genetracer Biotech of ... as a Certified Service Provider for Fluxion,s IsoFlux CTC ... in Genetracer Biotech,s novel liquid biopsy workflows for detection ... plans to move to other cancers as additional assays ... to isolate, recover, and analyze CTCs (circulating tumor cells) ...
(Date:2/25/2017)... Garden City, New York (PRWEB) , ... February ... ... announced their partnership with Verified Clinical Trials in an ongoing effort ... the areas of treatment, advocacy, and pharmaceutical research with emphasis on consumers and ...
(Date:2/24/2017)... 24, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... participate in its previously announced rights offering of ... of common stock and Series C Convertible Preferred ... warrants. As previously announced, the ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
Breaking Biology News(10 mins):